Glaukos GKOS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Glaukos in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Glaukos's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Glaukos's cash & equivalents?
- Glaukos (GKOS) reported cash & equivalents of $104.25M in Q1 2026.
- How has Glaukos's cash & equivalents changed year-over-year?
- Glaukos's cash & equivalents decreased by 8.8% year-over-year, from $114.25M to $104.25M.
- What is the long-term trend for Glaukos's cash & equivalents?
- Over 5 years (2020 to 2025), Glaukos's cash & equivalents has grown at a -1.2% compound annual growth rate (CAGR), from $96.6M to $90.81M.
- What does cash & equivalents mean?
- The total value of cash and highly liquid short-term investments that can be accessed immediately.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and financial flexibility, while a decrease may indicate heavy cash burn or significant capital deployment.
- How does cash & equivalents compare across companies?
- Standard across all industries; peers in medtech typically maintain high levels to support long R&D cycles.